1	Title
2	A multicenter study to assess the performance of the point-of-care RT-PCR Cobas SARS-
3	CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system in comparison with
4	centralized assays across healthcare facilities in the United States
5	
6	Authors
7	Elissa M. Robbins <sup>a#</sup>
8	Rasa Bertuzis <sup>a</sup>
9	Ho-Chen Chiu <sup>b</sup>
10	Lupe Miller <sup>a</sup>
11	Christopher Noutsios <sup>a</sup>
12	
13	Affiliations
14	<sup>a</sup> Roche Molecular Systems, Inc., Pleasanton, California, USA
15	<sup>b</sup> Roche Sequencing Solutions, Inc., Indianapolis, Indiana, USA
16	
17	*Corresponding author
18	Elissa M. Robbins
19	
20	Running title
21	POC SARS-CoV-2 & Influenza A/B test
	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### Non-structured abstract

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

Respiratory diseases can share many of the same symptoms, highlighting the need for timely and accurate differentiation to facilitate effective clinical management and reduce transmission. Compared with centralized testing, molecular point-of-care tests (POCT) can provide a faster time to result. We evaluated the RT-PCR POCT Cobas® SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas Liat® system (the POC SARS-CoV-2 & Influenza A/B test) in nasal and nasopharyngeal swab samples from 10 diverse healthcare facilities in the US. A composite comparator design consisting of three centralized tests was used to analyze SARS-CoV-2, whilst performance versus a single centralized test was used for analysis of influenza A and B. Evaluations included performance stratified by sample type (prospective/retrospective and nasal/nasopharyngeal [paired by subject]), collection method (self/healthcare workercollected [alternated and approximately balanced], symptom status (symptomatic/asymptomatic), and SARS-CoV-2 vaccination status, as well as assay inclusivity and system ease of use. A total of 2,247 samples were tested. For SARS-CoV-2, the overall percent agreement (OPA) was 98.8% (95% CI: 97.9, 99.3) in nasal swab samples and 99.0% (95% CI: 98.2, 99.4) in nasopharyngeal swab samples. Regression analysis showed that Ct values from paired nasal and nasopharyngeal swab samples were highly correlated (correlation coefficient 0.83). The OPA was ≥99.5% (sample type dependent) and 100.0% for influenza A and B, respectively. The POC SARS-CoV-2 & Influenza A/B test was easy to use. These results support the use of the POCT in various sample types and by various operators in the intended-use setting.

### **Summary statement/importance**

This study highlights the benefits of RT-PCR POCT, namely comparable performance to centralized testing in multiple sample types and ease of use. Utilizing assays such as the POC SARS-CoV-2 & Influenza A/B test may improve timely differentiation of respiratory diseases that share similar symptoms.

## Introduction

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

More than 4 years since the start of the coronavirus disease 2019 (COVID-19) pandemic, much of the world has returned to normality, yet COVID-19 continues to cause severe illness and mortality in the United States (US) and elsewhere(1, 2). This applies particularly for the immunocompromised, who are at risk of severe outcomes (3) and comprise approximately 3% of the US adult population(4). Disease activity is year-round, but seasonal spikes occur from November to April(5), coinciding with circulation of other respiratory viruses, such as influenza(6). Respiratory diseases such as COVID-19 and influenza share similar symptoms(7), highlighting the need for timely and accurate differentiation of the causative agent to help facilitate effective clinical management and reduce onward transmission. The current choice of testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is setting dependent(8), but standard laboratory-based (i.e., centralized) nucleic acid amplification tests are the mainstay of diagnosis(9). Numerous antigen or molecular pointof-care tests (POCT) are commercially available(10, 11), offering the benefit of a faster time to result(12). Both POCT formats have lower performance compared with centralized testing, particularly sensitivity (13) — a secondary analysis of antigen POCT found the performance to be commonly lower than stated within manufacturers' instructions for use (14) — but molecular POCT have relatively higher performance in comparison with antigen POCT, with pooled sensitivity values of 93% (99% specificity) versus 71% (99% specificity), respectively(13). Molecular POCT can provide actionable results in as little as 20 minutes depending on the assay and workflow(11).

Influenza is a significant cause of severe illness and death(15-17), resulting in a substantial clinical burden to patients and the healthcare system alike(18). Molecular POCT for the detection of influenza A/B subtypes, and other respiratory viruses such as respiratory syncytial virus, have been available for several years(11, 12, 19-22). Clinical practice quidelines from the Infectious Diseases Society of America recommend that antivirals are initiated for certain patient groups as soon as possible regardless of illness duration, or within 48 hours of illness onset(23), supporting the use of rapid molecular POCT for influenza testing in preference to centralized laboratory testing. In the hospital setting, an interventional study of a molecular POCT for influenza found significant improvements in isolation practices and reductions in length of stay compared with centralized testing(24), whilst a modeling study found that the introduction of POCT could reduce time to diagnosis, hospital stay, and in-hospital costs(25). Molecular POCT for influenza can generate sensitivity estimates of  $\geq$ 96–100% in real-world settings(22, 26). The primary objective of this study was to evaluate the real-world clinical performance of the POC Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas Liat system (herein referred to as the POC SARS-CoV-2 & Influenza A/B), a multiplexed RT-PCR test combining measurement of SARS-CoV-2 and influenza subtypes, in reference to comparator centralized PCR tests for SARS-CoV-2 and influenza A and B viruses. Sample types were nasal and nasopharyngeal swab specimens from individuals suspected of respiratory viral infection consistent with COVID-19, and asymptomatic individuals exposed to COVID-19, who presented at healthcare facilities across the US during the COVID-19 public health emergency. Secondary objectives were to evaluate the influence of collection method and the ease of use of the Cobas Liat system.

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

## **Materials and methods**

**Sites** 

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

Testing was conducted at 11 sites: 10 geographically diverse healthcare facilities that were representative of intended-use sites (i.e., POC settings, such as emergency departments, urgent care, pediatric and primary care clinics, and drive-through COVID-19 testing sites), and one reference laboratory for centralized testing. After testing using the POC SARS-CoV-2 & Influenza A/B test at the healthcare facilities, samples were shipped to the reference laboratory for analysis with the comparator assays (see below). Healthcare facilities were selected based on sample availability, ability to provide adequate resources and operators, ability to adhere to good clinical practice, and with the aim of ensuring representation of the demographic diversity of the US population. Not all healthcare facilities performing testing were certified under Clinical Laboratory Improvement Amendments (CLIA) regulations to perform waived testing, but all facilities met the requirements for CLIA-waived settings (i.e., intended-use settings using untrained nonlaboratory personnel). All healthcare facilities performed both sample collection and POC testing. POC operators at the 10 healthcare facilities (n=30 operators in total) had limited or no laboratory training and were representative of typical test operators in CLIA-waived settings (e.g., nurses, nursing assistants, and medical assistants). Operators at the reference laboratory were blinded to the results generated at the healthcare facilities. Study population The symptomatic group comprised samples from individuals with suspected respiratory viral infection consistent with COVID-19 (see Signs/symptoms, Supplementary material). The

asymptomatic group comprised individuals with self-reported 'recent' exposure (timeframe

undefined) to SARS-CoV-2-positive individuals or any other reasons to suspect COVID-19.

Patient clinical information was gathered, including, but not limited to, antiviral usage for up

perpetuity.

It is made available under a CC-BY 4.0 International license .

to 7 days prior to and on the day of sample collection, gender, race/ethnic group, and age. Individuals presenting at the healthcare facilities were considered for study inclusion, subject to the eligibility criteria (see Eligibility criteria, Supplementary material). Study design The clinical performance of the POC SARS-CoV-2 & Influenza A/B test (27) was evaluated by comparing results to a composite comparator method for the SARS-CoV-2 analyte using the following three highly sensitive centralized testing assays: Cobas SARS-CoV-2 qualitative assay for use on the Cobas 6800/8800 systems (herein referred to as the 6800/8800 SARS-CoV-2 test)(28); Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas 6800/8800 systems (herein referred to as the 6800/8800 SARS-CoV-2 & Influenza A/B test)(29); and Hologic® Aptima® SARS-CoV-2 Assay(30). The clinical performance for the influenza A/B analyte components of the POC SARS-CoV-2 & Influenza A/B test was evaluated against a single centralized testing assay, the 6800/8800 SARS-CoV-2 & Influenza A/B (29). Samples that generated invalid results were repeated where sample volume permitted additional testing; samples generating a second invalid result upon retesting were reported as invalid. Interrogation of discrepant samples was not performed, though selected samples were further retested with the POC SARS-CoV-2 & Influenza A/B test for exploratory purposes. Sample types and collection Sample types included fresh and frozen nasal and nasopharyngeal swab samples, collected in the same media formulations but under different brand names: Copan Universal Transport Medium (UTM) or BD Universal Viral Transport (UVT) medium.

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

Prospective fresh samples (UTM)

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

One nasal swab and one nasopharyngeal swab sample were collected from each study participant. A nasal swab of both nostrils was first collected either by the healthcare worker (HCW), herein referred to as 'HCW-collected', or by the study participant under instruction from the HCW, herein referred to as 'self-collected', as per manufacturer's instructions.(31) A nasopharyngeal swab was then collected by HCWs from the same study participant to generate paired samples. If a nasopharyngeal swab had already been collected (using one nostril) as part of the healthcare facility's standard of care, the study nasopharyngeal swab was taken from the opposite nostril. All prospective samples were collected from patients presenting to healthcare facilities during February to June 2022, characteristic of the 2021/2022 winter respiratory season. Retrospective frozen samples (archived or purchased from external vendors; UTM or UVT) The low influenza prevalence in the prospective population was anticipated because of reduced international travel, new respiratory care paradigms, increased public health awareness, and use of interventions (such as masking policies or social distancing) that occurred during the COVID-19 pandemic and study enrollment period, in which influenza A virus had been the dominant virus type in circulation. (32) Therefore, frozen samples positive for influenza A virus and for influenza B virus were used to supplement the prospectively collected fresh samples. These retrospective samples were collected in the US during the 2013–2014, 2014–2015, and 2019–2020 influenza seasons. Baseline demographic data and patient characteristics related to these samples were unavailable. Retrospective samples with known SARS-CoV-2 status, collected between March 29, 2021 and May 26, 2021, were also included in the SARS-CoV-2 analyses.

Whilst multiple freeze-thaw cycles have a limited effect on the viral titer(33), there is the potential for samples that were initially low-titer positives to appear negative following storage. Internal Roche data support the stability of viral titer for up to three freeze-thaw cycles, so retrospective samples were only eligible for inclusion if they had undergone no more than two freeze-thaw cycles. Retrospective positive and negative samples were blended in a standard POCT workflow and assessed alongside prospectively collected samples.

## **Details of assays and instruments**

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

POC SARS-CoV-2 & Influenza A/B test (POC RT-PCR)

The Cobas Liat analyzer is for in vitro diagnostic use(27). The analyzer automates all nucleic acid amplification test processes, including target enrichment, inhibitor removal, nucleic acid extraction, reverse transcription, DNA amplification, real-time detection, and result interpretation in approximately 20 minutes(27). The Cobas Liat system comprises the Cobas Liat analyzer in conjunction with the Cobas Liat assay tubes (27). The POC SARS-CoV-2 & Influenza A/B test utilizes a single-use disposable assay tube that contains all the reagents necessary for the detection of SARS-CoV-2 and hosts the sample preparation and PCR processes(34). This multiplex real-time RT-PCR test is intended for the simultaneous rapid *in vitro* qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B virus RNA in healthcare provider-collected nasal and nasopharyngeal swab samples and self-collected nasal swab samples (collected in a healthcare setting with

instruction by a healthcare provider) from individuals suspected of respiratory viral infection

consistent with COVID-19(34).

6800/8800 SARS-CoV-2 & Influenza A/B test (centralized testing method [CTM] 1) The Cobas 6800/8800 systems consist of the sample supply module, the transfer module, the processing module, and the analytic module (29). Automated data management is performed by the Cobas 6800/8800 software, which assigns results for all tests. Results are available within less than 3.5 hours after loading the sample on the system. (29) The positive SARS-CoV-2 result is defined as positive on the SARS-CoV-2 channel (Target 2) and/or the pan-sarbeco channel (Target 3). The 6800/8800 SARS-CoV-2 & Influenza A/B test is an automated multiplex real-time RT-PCR assay intended for simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A virus, and/or influenza B virus RNA in healthcare provider-collected nasal and nasopharyngeal swab samples and self-collected nasal swab samples (collected in a healthcare setting with instruction by a healthcare provider) from individuals suspected of respiratory viral infection consistent with COVID-19(29). 6800/8800 SARS-CoV-2 test (CTM 2) The 6800/8800 SARS-CoV-2 test is an automated real-time RT-PCR assay intended for the qualitative detection of nucleic acids from SARS-CoV-2 in healthcare provider-instructed, self-collected anterior nasal (nasal) swab samples (collected onsite) and healthcare providercollected nasal, nasopharyngeal, and oropharyngeal swab samples collected from any individuals, including those suspected of COVID-19 by their healthcare provider, and those without symptoms or with other reasons to suspect COVID-19(28). The positive SARS-CoV-2 result is defined as positive on the SARS-CoV-2 channel (Target 1) and/or the pan-sarbeco channel (Target 2).

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

Hologic Aptima SARS-CoV-2 assay (tiebreaker; CTM 3) As a commonly used molecular assay(30), CTM 3 was utilized as a tiebreaker. The test utilizes transcription-mediated amplification for the qualitative detection of RNA from SARS-CoV-2 isolated and purified from nasopharyngeal, nasal, mid-turbinate and oropharyngeal swab samples, nasopharyngeal wash/aspirate, or nasal aspirates obtained from individuals meeting COVID-19 clinical and/or epidemiological criteria(35). **Analyses** All data analyses were performed using SAS/STAT® software (v9.4 or higher of the SAS System for Linux). No formal sample size calculations were calculated for this study, but patient enrollment was adjusted to accommodate disease prevalence and to generate a minimum of 50 SARS-CoV-2 positives, 30 influenza A positives, and 10 influenza B positives for analysis. The clinical performance of the POC SARS-CoV-2 & Influenza A/B test was evaluated using estimates of positive percent agreement (PPA), negative percent agreement (NPA), and overall percent agreement (OPA), calculated with 2-sided 95% confidence intervals (CI) using the Wilson-score method(36). Comparison was against either the composite comparator for SARS-CoV-2 (CTM 1, CTM 2, and CTM 3 [tiebreaker if required]) or a single comparator for influenza A/B (CTM 1). For SARS-CoV-2, concordant results from CTM 1 and CTM 2 established true positive or true negative status. In the event of discordance between CTM 1 and CTM 2, CTM 3 (the tiebreaker) was used to establish true status. Samples could be coded as uninterpretable in the event of invalid, failed, aborted or missing results that were not resolved upon retesting. If CTM 1 or CTM 2 or CTM 3 returned uninterpretable results, and the other two methods returned different results (i.e., CTM 1 positive, CTM 2 negative, and CTM 3 uninterpretable), then the status of the sample would be described as indeterminate.

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

perpetuity.

It is made available under a CC-BY 4.0 International license .

McNemar's mid-p test (P-value) was used to assess any differences between sample types. A P-value of <0.05 was considered statistically significant. POCT operators were asked to complete a questionnaire to evaluate the ease of use of the POC SARS-CoV-2 & Influenza A/B test. In silico analysis of the POC SARS-CoV-2 & Influenza A/B test was performed to assess assay design inclusivity on all available SARS-CoV-2 sequences (taxonomy ID 2697049) in the Global Initiative on Sharing All Influenza Data (GISAID) and National Center for Biotechnology Information (NCBI) databases up to July 2024 (>16,800,000 sequences in NCBI and >8,900,000 sequences in GISAID). The predicted impact of each variant on gene target 1 and gene target 2 primer and probe binding site sequence was evaluated using Roche proprietary software and Melting5 software. A SARS-CoV-2 sequence would be potentially not detected by the POC SARS-CoV-2 & Influenza A/B test if a delay in cycle threshold greater than five cycles and/or a probe melting temperature of <65°C was predicted. **Ethics statement** This study was a non-interventional evaluation of an *in vitro* diagnostic device (test results were not used to inform patient care decisions). This study was conducted in compliance with International Conference on Harmonisation Good Clinical Practice guidelines, regulations of the US Food and Drug Administration (FDA), and the Declaration of Helsinki. The study protocol was submitted to Institutional Review Boards (IRBs) in accordance with FDA and local regulatory requirements before the start of the study. The following IRBs gave permission for this study to be performed: NorthShore University Health System Institutional Review Board; University of Rochester, Research Subjects Review Board; and Western IRB.

# 11

**Results** 

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

perpetuity.

It is made available under a CC-BY 4.0 International license.

Participants and summary of testing results Subjects from 10 geographically diverse healthcare facilities were enrolled in the study. The summary of testing results can be seen in **Supplemental Table A**. A total of 2,209 SARS-CoV-2 results from prospective samples (both nasal and nasopharyngeal swabs) were valid for inclusion in downstream analyses. Population and baseline characteristics Baseline demographic data for study participants were available for the prospectively collected samples; details on the study participants are presented in **Table 1**. Of these subjects, 506 were male (47.8%) and 553 were female (52.2%). The median age was 35 years (range 0-86). Patient characteristics are present in **Supplemental Table B**. In total, 60.4% of subjects in the prospective population had signs and symptoms of respiratory infection, with days from onset of first symptom ranging from 1 to 365 days. The remaining 39.6% of subjects were asymptomatic but were clinically suspected of SARS-CoV-2 infection by their healthcare provider due to recent exposure or other reason. The nasal swab samples were evenly distributed between HCW-collected and self-collected. **Medical history** The medical history relating to vaccination status is presented in **Table 2**. Most participants received a COVID-19 vaccine (68.7%), with Pfizer as the most common vaccine for both first and second doses (69.5% and 72.2%, respectively). SARS-CoV-2 Determination of the composite comparator status for SARS-CoV-2 In symptomatic study participants, the composite comparator method was SARS-CoV-2 positive for 134 nasal and 131 nasopharyngeal swab samples (**Supplemental Table C**).

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

In asymptomatic study participants, the composite comparator method was SARS-CoV-2 positive for 39 nasal and 39 nasopharyngeal swab samples (**Supplemental Table C**). Performance The total number of samples that were positive, negative, or invalid, and how these align with the composite comparator status, can be seen in **Figure 1**. The diagnostic performance (total number of positive and negative results) for SARS-CoV-2 can be seen in **Table 3.** Agreement between the composite comparator and the POC SARS-CoV-2 & Influenza A/B test for detection of SARS-CoV-2 in nasal swabs (total, prospective and retrospective, self-collected or HCW-collected), nasopharyngeal swabs (total, prospective and retrospective), in samples from vaccinated and unvaccinated participants, and in symptomatic and asymptomatic participants can be seen in **Supplemental Table D**. For nasal swab samples, the total OPA, PPA, and NPA was 98.8% (95% CI: 97.9, 99.3), 97.1% (95% CI: 93.3, 98.7), and 99.1% (95% CI: 98.2, 99.5), respectively. Of note, the OPA for HCW-collected nasal swab samples was 98.4% (95% CI: 97.0, 99.2) and 99.1% (95% CI: 98.0, 99.6) for self-collected nasal swab samples. The total OPA, PPA, and NPA for nasopharyngeal swab samples was 99.0% (95% CI: 98.2, 99.4), 96.4% (95% CI: 92.4, 98.4), and 99.4% (95% CI: 98.7, 99.8), respectively. Using all paired results for nasal and nasopharyngeal swab samples by subject, the swab type did not make a difference in the reported result (McNemar's mid-p test, P=0.771). Cycle threshold (Ct) value distributions The range of Ct values in nasal and nasopharyngeal swab samples can be seen in Figure 2. Self-collected nasal swabs showed the highest average viral load followed by

nasopharyngeal swabs, then HCW-collected nasal swabs.

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

perpetuity.

It is made available under a CC-BY 4.0 International license .

The range of Ct values in subject-paired nasal and nasopharyngeal swab samples can be seen in **Figure 3**. The Deming regression analysis showed that the two sample types were highly correlated (**Figure 3A**; r = 0.83). Exploration of the collection method showed that HCW-collected nasal swabs had greater concordance between the paired samples (Figure **3B**; r = 0.91) than the self-collected nasal swabs (r = 0.77; **Figure 3C**). **Discordance** Fourteen nasal and 11 nasopharyngeal swab samples showed discordant results between the POC SARS-CoV-2 & Influenza A/B test and the centralized testing methods (Supplemental Table E); 10 were positive only on the POC SARS-CoV-2 & Influenza A/B test. Influenza A Performance The agreement between the POC SARS-CoV-2 & Influenza A/B test and the 6800/8800 SARS-CoV-2 & Influenza A/B test for detection of influenza A in nasopharyngeal swabs (total, prospective and retrospective) and nasal swabs (total, prospective and retrospective, HCW-collected or self-collected) can be seen in **Supplemental Table F**. The OPA ranged from 98.9% to 100.0%. **Discordance** Two nasal and five nasopharyngeal swab samples showed discordant results between the POC SARS-CoV-2 & Influenza A/B test and the 6800/8800 SARS-CoV-2 & Influenza A/B test for detection of influenza A (**Supplemental Table G**), four of which were positive only on the POC SARS-CoV-2 & Influenza A/B test. Influenza B

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

Performance The agreement between the POC SARS-CoV-2 & Influenza A/B test and the 6800/8800 SARS-CoV-2 & Influenza A/B test for detection of influenza B in nasopharyngeal swabs (total, prospective and retrospective) and nasal swabs (total, prospective and retrospective, self-collected nasal or HCW-collected) can be seen in **Supplemental Table H**. The OPA for all comparisons was 100.0%. <u>Discordance</u> No discordant results between the POC SARS-CoV-2 & Influenza A/B test and the 6800/8800 SARS-CoV-2 & Influenza A/B test for detection of influenza B were recorded. **Evaluation of the ease of use for the Cobas Liat system** Twenty-seven operators with experience of testing samples on the Cobas Liat completed the questionnaire. The operators' average scores indicating their agreement with the statements in the questionnaire are shown in **Supplemental Table I**. The overall score was 4.5 out of 5 for the operators' answers to all eight statements, indicating that the operators agreed that the Cobas Liat system was easy to use. **Inclusivity analysis** The POC SARS-CoV-2 & Influenza A/B test targets the nucleocapsid (N) and ORF1a/b regions of the SARS-CoV-2 genome.(34) In silico analysis showed that 99.98% of NCBI and 99.99% of GISAID sequences for SARS-CoV-2 had no changes in the primer/probe binding sites of both target regions simultaneously. All sequences were predicted to be detected by at least one of the two sites. **Discussion** 

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

perpetuity.

It is made available under a CC-BY 4.0 International license.

In this study, we evaluated the performance of the POC SARS-CoV-2 & Influenza A/B test against up to three centralized assays, stratified by various parameters. The high performance of the POC SARS-CoV-2 & Influenza A/B test in comparison with centralized testing methods utilizing nasopharyngeal or nasal samples has previously been reported(37-41), but this study is the first to report the performance of the POC SARS-CoV-2 & Influenza A/B test across variables such as collection method (self/HCW, retrospective/prospective), vaccination status, symptom status, and ease of use. Using the comparator result to establish the status of infection, we found high agreement between the POC RT-PCR test and the centralized testing assays for all three analytes across all variables. Previously, a meta-analysis of nucleic acid amplification testing reported that the sensitivity for detection of SARS-CoV-2 in nasal samples may be less than nasopharyngeal samples(42), whilst a study specifically assessing the POC SARS-CoV-2 & Influenza A/B test reported similar differences in SARS-CoV-2 detection by sample type(37). However, we saw no evidence of a sample-type difference in sensitivity, with SARS-CoV-2 positivity identified in both nasal and nasopharyngeal swab samples to a similar extent (POC SARS-CoV-2 & Influenza A/B test positivity rate approximately 15%; the difference in sensitivity [nasal minus nasopharyngeal] was +0.9%). A small study from Denmark found almost equivalent sensitivity for detection of SARS-CoV-2 using self- and HCW-collected samples (84.2% vs 89.5%, respectively), and that patients preferred self-collection(43). In our study, whether nasal samples were collected by HCWs or by the patients themselves had little impact on the agreement values between the POC RT-PCR test and the comparators. Indeed, in all comparisons the agreement for selfcollected samples was actually higher than for HCW-collected samples. For SARS-CoV-2, Ct values of paired nasal and nasopharyngeal swab samples as measured by the POC RT-PCR test were highly correlated, and Ct values were on average lower in nasal swab samples (i.e., higher viral RNA titer) compared with nasopharyngeal swab samples, with self-

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

collected nasal swabs exhibiting the lowest Ct values. Collectively, this indicates that the high performance level of the POC RT-PCR test is maintained across collection methods, and that patients are able to self-sample effectively, and are willing to do so. We identified a small number of discrepant samples for the SARS-CoV-2 analyte in both nasal and nasopharyngeal swab samples, consistent with other studies (37, 38), most of which were false positives. The majority of the false positives were in the high Ct/low viral titer range (POC SARS-CoV-2 & Influenza A/B test Ct values: lowest 28.2, median 35.2, highest 37.1) and thus close to or at the lower limit of detection of Ct 35.2 (USA-WA1/2020 strain) for the POC SARS-CoV-2 & Influenza A/B test(34). Of the false negatives detected by the POC SARS-CoV-2 & Influenza A/B test, all except one sample were in the high Ct range. Indeed, after exploratory re-testing of false-negative nasopharyngeal samples, two were found to be positive (re-tested Ct values were 34.8 and 35.4). Generally, low viral burden can be a cause of discrepant results(44), and a small external quality assessment (reproducibility) study reported that the performance of the POC SARS-CoV-2 & Influenza A/B test is highest at low Ct values(45). US legislation categorizes tests for complexity (moderate or high) using seven criteria, such as the need for training and experience, and assigns scores within each criterion(45). Test systems can be assigned as 'waived complexity' under certain conditions, and these tests require no formal operator training or competency(45). In addition to CLIA-certified laboratories, the POC SARS-CoV-2 & Influenza A/B test is authorized for use in patient care settings that are CLIA waived(34). In conjunction with the fast turnaround offered by the Cobas Liat system and demonstrated in studies of the POC SARS-CoV-2 & Influenza A/B test in real-world settings (40, 46) or studies evaluating workflow or processing time(41, 47), our study confirms that the POC SARS-CoV-2 & Influenza A/B test is easy to use in CLIA-waived settings, and offers results in a timeframe conducive for rapid patient management.

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

The strength of our multicenter study lies in the comprehensive nature of the variables assessed, encompassing a wide variety of patient characteristics likely to be encountered in healthcare settings. The study included a prospectively enrolled cohort of patients seeking care, which is representative of the intended-use population of the POC SARS-CoV-2 & Influenza A/B test. Our study has some limitations. Firstly, we did not ascertain the SARS-CoV-2 variants present in the samples. Whilst the emergence of SARS-CoV-2 variants has the ability to affect the diagnostic performance of the test, previous studies have indicated that the POC SARS-CoV-2 & Influenza A/B test detects both wild-type and variants of concern, such as Alpha (B.1.1.7) or Omicron (B.1.1.529)(39, 47). Bioinformatic analysis to assess inclusivity showed that the POC SARS-CoV-2 & Influenza A/B test is predicted to bind all sequences available in the NCBI and GISAID databases as of July 2024. The dual target assay design helps to ensure that the assay is robust and safeguards against the emergence of variants that have the potential to affect assay performance and evade detection.

## **Conclusion**

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

A POC RT-PCR test combining both measurement of SARS-CoV-2 and influenza subtypes with performance equivalent to routine centralized testing would provide a critical tool to improve the diagnosis and management of COVID-19 and influenza. We found that the performance of the POC SARS-CoV-2 & Influenza A/B test was comparable to centralized testing methods. With the ease of use and equivalent performance, it highlights the question as to whether centralized testing should be considered as the gold standard. A study of the POC Cobas Influenza A/B test (a Liat RT-PCR test that detects only the influenza analyte) in the emergency department found that POC testing for influenza was useful in improving several metrics, including the indication for treatment with neuraminidase in positive cases(48). It is relevant to note that SARS-CoV-2 and influenza coinfection can increase the risk of severe outcomes compared with those infected with SARS-CoV-2 alone, particularly for those coinfected with influenza A.(49) Our study highlights the benefits of molecular

multiplex POCT to help improve timely differentiation of respiratory diseases that share similar symptoms and support efforts to improve patient management. **Funding** This study was funded by Roche Molecular Systems, Inc (Pleasanton, California, USA). **Disclosures** EMR, RB, HC, LM, and CN are employees of Roche Molecular Systems, Inc. EMR participates in Roche Connect and is a shareholder. Assay disclaimers The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas Liat system (herein referred to as the POC SARS-CoV-2 & Influenza A/B test) was originally approved under Emergency Use Authorization EUA201779 and has since been cleared and Clinical Laboratory Improvement Amendments (CLIA) waived under 223591/CW220014, respectively, in the US and is CE-IVD marked in the European Union. Sample collection in the patient's home is not approved in the US or European Union. The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas 6800/8800 systems (herein referred to as the 6800/8800 SARS-CoV-2 & Influenza A/B test) is authorized only for use under Emergency Use Authorization (EUA) in the US, and is CE-IVD marked in the European Union. The assay is not approved for use in asymptomatic patients in the US or European Union. The assay is not approved for use as a point-of-care (POC) test/near-patient test (NPT) in the US/European Union. Sample collection in the patient's home is not approved in the US or European Union. The Cobas SARS-CoV-2 qualitative assay for use on the Cobas 6800/8800 systems (herein referred to as the 6800/8800 SARS-CoV-2 test) is authorized only for use under EUA in the US, and is CE-IVD marked in the European Union. The assay is not approved for use as a

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

POC test/NPT in the US/European Union. Sample collection in the patient's home is not approved in the US or European Union. Hologic Aptima SARS-CoV-2 assay is an FDA EUA assay.(30) **Data availability** The datasets generated during and/or analyzed during the current study are not publicly available due to patient confidentiality. Any access requests from qualified researchers should be submitted directly to the Ethical Committee of each participating study site. **Acknowledgments** Medical writing support was provided by Corrinne Segal of Obsidian Healthcare Group Ltd (London, UK) and was funded by Roche Molecular Systems, Inc. COBAS and LIAT are trademarks of Roche. All other product names and trademarks are the property of their respective owners. We would like to thank Saima Shams and Vaishali Mody for their contributions to the development of the Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas Liat system (herein referred to as the POC SARS-CoV-2 & Influenza A/B test), and

452

453

454

455

456

457

458

459

460

461

462

463

464

465


466

467

Jingtao Sun for his bioinformatics expertise.

## **Figures**

- Figure 1: Detection of SARS-CoV-2 using the POC SARS-CoV-2 & Influenza A/B test and the composite comparator (prospective and
- retrospective, symptomatic and asymptomatic subjects)<sup>a</sup>




471 472

468

469

- Abbreviations: CC, composite comparator; POC RT-PCR, point-of-care RT-PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
- 473 aThe composite comparator comprises the 6800/8800 SARS-CoV-2 & Influenza A/B test, 6800/8800 SARS-CoV-2 test, and Hologic® Aptima®
- 474 SARS-CoV-2 Assay; the POC RT-PCR test is the POC SARS-CoV-2 & Influenza A/B test.
- The Cobas® SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat® system is herein referred to as the POC SARS-CoV-2 &
- 476 Influenza A/B test. The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas 6800/8800 systems is herein referred to as
- the 6800/8800 SARS-CoV-2 & Influenza A/B test. Cobas SARS-CoV-2 qualitative assay for use on the Cobas 6800/8800 systems is herein
- 478 referred to as the 6800/8800 SARS-CoV-2 test.

## Figure 2: Ct values for the SARS-CoV-2 analyte from the POC SARS-CoV-2 & Influenza A/B test in nasal and nasopharyngeal swab samples<sup>a</sup>



22.8, minimum Ct 10.6, maximum Ct 37.1.


Abbreviations: Ct, cycle threshold; HCW, healthcare worker-collected; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup>False positives are represented by black circles. Cross represents mean Ct values. Nasal (total): n=179, mean Ct 23.1, median Ct 21.9, minimum Ct 11.0, maximum Ct 36.8; HCW-collected nasal: n=87, mean Ct 23.9, median Ct 23.7, minimum Ct 12.3, maximum Ct 36.8; self-collected nasal: n=92, mean Ct 22.4, median Ct 21.1, minimum Ct 11.0, maximum Ct 36.1; nasopharyngeal: n=177, mean Ct 23.4, median Ct 21.1, minimum Ct 11.0, maximum Ct 36.1; nasopharyngeal: n=177, mean Ct 23.4, median Ct 21.1, minimum Ct 11.0, maximum Ct 36.1; nasopharyngeal: n=177, mean Ct 23.4, median Ct 23.4, medi

False positives are indicated by black circles. The Cobas® SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat® system is herein referred to as the POC SARS-CoV-2 & Influenza A/B test. Horizontal solid line represents median values. Upper and lower boundaries of box plot represent 75th and 25th percentile.

Figure 3: Deming regression for the SARS-CoV-2 analyte from the POC SARS-CoV-2 & Influenza A/B test in subject-paired nasal and nasopharyngeal swab samples<sup>a</sup>

## A: Nasal (total); B: HCW-collected nasal swab; C: Self-collected nasal swab



Abbreviations: Ct, cycle threshold; FP, false positive; HCW, healthcare worker-collected; NPS, nasopharyngeal swab; NS, nasal; NS FP, nasal false positive; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup>The Cobas<sup>®</sup> SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat<sup>®</sup> system is herein referred to as the POC SARS-CoV-2 & Influenza A/B test. Prospective symptomatic = open circle; prospective exposed = triangle. Dashed line represents perfect correlation. Solid line represents Deming regression. Red data points represent HCW-collected nasal swabs. Blue data points represent self-collected nasal swabs.

## **Tables**

500

501

# Table 1: Demographics (prospective symptomatic and asymptomatic subjects)

Characteristics	Prospective population
Total	
N	1,059
Age (years)	
Mean	34.2
Standard deviation	19.88
Median	35.0
Range (minimum–maximum) <sup>a</sup>	0.0-86.0
Age group (years), n (%)	
≤18	287 (27.1)
19–39	319 (30.1)
40-64	391 (36.9)
≥65	62 (5.9)
Sex at birth, n (%)	
Male	506 (47.8)
Female	553 (52.2)
Ethnicity, n (%)	
Hispanic/Latino	212 (20.0)
Not Hispanic/not Latino	589 (55.6)
Not reported <sup>b</sup>	236 (22.3)
Unknown <sup>c</sup>	22 (2.1)
Race, n (%)	
American Indian/Alaskan Native	3 (0.3)
Asian	37 (3.5)
Black/African American	175 (16.5)
Native Hawaiian/Pacific Islander	6 (0.6)
White	520 (49.1)
Other	56 (5.3)
Not reported <sup>b</sup>	262 (24.7)
	·

503 <sup>a</sup>All subjects <1 year old are counted as age 0. 504 <sup>b</sup>A clinical site that was a mobile drive-through site was not able to collect race/ethnicity 505 identification from subjects. 506 <sup>c</sup>Unknown category indicates subjects for whom the corresponding information is not 507 available. 508

# Table 2: Subject medical history (prospective symptomatic and asymptomatic subjects)

Characteristics	Population statistics
Total	
N	1,059
Subject received the influenza vaccine within th	e last 6 weeks, n (%)
Yes	14 (1.3)
No	1,045 (98.7)
Unknown	0 (0.0)
Influenza vaccine route of administration, n (%	)²
Intramuscular	14 (100.0)
Intranasal	0 (0.0)
Unknown	0 (0.0)
Subject received a COVID-19 vaccine, n (%)	
Yes	728 (68.7)
No	303 (28.6)
Unknown	28 (2.6)
Type of COVID-19 vaccine received for first dose	e, n (%) <sup>b</sup>
Pfizer	506 (69.5)
Moderna	185 (25.4)
Johnson & Johnson (J & J)	30 (4.1)
Other	3 (0.4)
Unknown	4 (0.5)
Type of COVID-19 vaccine received for second d	lose, n (%) <sup>b</sup>
Pfizer	488 (72.2)
Moderna	182 (26.9)
Other	3 (0.4)
Unknown	3 (0.4)
Type of COVID-19 vaccine received first booster	, n (%) <sup>b,c</sup>
Pfizer	217 (64.0)
Moderna	115 (33.9)
Johnson & Johnson (J & J)	5 (1.5)

509

Characteristics	Population statistics	
Other	1 (0.3)	
Unknown	1 (0.3)	

511	
512	Abbreviations: COVID-19, coronavirus disease 2019
513	<sup>a</sup> Percentages calculated based on number of subjects who received the influenza vaccine
514	within the last 6 weeks prior to enrollment and sample collection.
515	<sup>b</sup> Percentages calculated based on number of subjects who received COVID-19 vaccine or
516	first booster.
310	inse booseer.
517	<sup>c</sup> There were six subjects that reported receiving a second booster.
518	

# Table 3: Results for the detection of SARS-CoV-2 using the composite comparator compared with the POC SARS-CoV-2 & Influenza A/B test<sup>a</sup>

	Composite comparator (+)	Composite comparator (-)	Total	PPA % (95% CI)	NPA % (95% CI)
Nasal					
POC SARS-CoV-2 & Influenza A/B test (+)	165	9	174	97.1 (93.3, 98.7)	99.1 (98.2, 99.5)
POC SARS-CoV-2 &	5	961	966		
Influenza A/B test (-)					
Total	170	<i>970</i>	1,140		
Nasopharyngeal					
POC SARS-CoV-2 & Influenza A/B test (+)	162	5	167	96.4 (92.4, 98.4)	99.4 (98.7, 99.8)
POC SARS-CoV-2 & Influenza A/B test (-)	6	896	902		
Total	168	901	1,069		

522 Abbreviations: CI, Score confidence interval; NPA, negative percent agreement; PPA, positive percent agreement; SARS-CoV-2, severe acute 523

respiratory syndrome coronavirus 2.

<sup>a</sup>The Cobas<sup>®</sup> SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat<sup>®</sup> system is herein referred to as the POC SARS-CoV-2 &

525 Influenza A/B test.

520

521

## References

526

527 1. Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, Macdonald B, Dattani S, Beltekian D, Ortiz-Ospina E, Roser M. 2020. Coronavirus 528 529 pandemic (COVID-19). https://ourworldindata.org/coronavirus. Accessed Mar 06, 2024. 530 531 2. Ahmad FB, Cisewski JA, Xu J, Anderson RN. 2023. COVID-19 Mortality Update 532 - United States, 2022. MMWR Morb Mortal Wkly Rep 72:493–496. Meyerowitz EA, Scott J, Richterman A, Male V, Cevik M. 2023. Clinical course 533 3. 534 and management of COVID-19 in the era of widespread population immunity. Nat Rev Microbiol 22:75-88. 535 536 4. Antinori A, Bausch-Jurken M. 2023. The burden of COVID-19 in the 537 immunocompromised patient: implications for vaccination and needs for the future. J Infect Dis 228:S4-S12. 538 5. Wiemken TL, Khan F, Puzniak L, Yang W, Simmering J, Polgreen P, Nguyen 539 JL, Jodar L, McLaughlin JM. 2023. Seasonal trends in COVID-19 cases, 540 541 hospitalizations, and mortality in the United States and Europe. Sci Rep 13:3886. 542 543 6. Moriyama M, Hugentobler WJ, Iwasaki A. 2020. Seasonality of Respiratory 544 Viral Infections. Annu Rev Virol 7:83–101. World Health Organization. 2024. Coronavirus disease (COVID-19): 545 7. similarities and differences between COVID-19 and influenza. 546 547 https://www.who.int/news-room/guestions-and-answers/item/coronavirusdisease-covid-19-similarities-and-differences-with-influenza. Accessed Aug 05, 548 2024. 549

perpetuity.

It is made available under a CC-BY 4.0 International license .

550 8. Baldanti F, Ganguly NK, Wang G, Möckel M, O'Neill LA, Renz H, Dos Santos 551 Ferreira CE, Tateda K, Van Der Pol B. 2022. Choice of SARS-CoV-2 diagnostic 552 test: challenges and key considerations for the future. Crit Rev Clin Lab Sci 553 59:445-459. 554 9. Hayden MK, Hanson KE, Englund JA, Lee MJ, Loeb M, Lee F, Morgan DJ, Patel R, El Mikati IK, Igneibi S, Alabed F, Amarin JZ, Mansour R, Patel P, Falck-Ytter 555 556 Y, Morgan RL, Murad MH, Sultan S, Bhimraj A, Mustafa RA. 2023. The 557 Infectious Diseases Society of America guidelines on the diagnosis of 558 coronavirus disease 2019 (COVID-19): molecular diagnostic testing. Clin 559 Infect Dis doi:10.1093/cid/ciad646. Katzenschlager S, Brümmer LE, Schmitz S, Tolle H, Manten K, Gaeddert M, 10. 560 Erdmann C, Lindner A, Tobian F, Grilli M, Pollock NR, Macé A, Erkosar B, 561 562 Carmona S, Ongarello S, Johnson CC, Sacks JA, Denkinger CM, Yerlikaya S. 2023. Comparing SARS-CoV-2 antigen-detection rapid diagnostic tests for 563 COVID-19 self-testing/self-sampling with molecular and professional-use 564 565 tests: a systematic review and meta-analysis. Sci Rep 13:21913. 566 Tolan NV, Horowitz GL. 2022. Clinical diagnostic point-of-care molecular 11. assays for SARS-CoV-2. Clin Lab Med 42:223-236. 567 12. 568 Shirley JD, Bennett SA, Binnicker MJ. 2023. Current regulatory landscape for 569 viral point-of-care testing in the United States. J Clin Virol 164:105492. Fragkou PC, Moschopoulos CD, Dimopoulou D, Ong DSY, Dimopoulou K, 570 13. Nelson PP, Schweitzer VA, Janocha H, Karofylakis E, Papathanasiou KA, 571 572 Tsiordras S, De Angelis G, Thölken C, Sanguinetti M, Chung HR, Skevaki C. 573 2023. Performance of point-of care molecular and antigen-based tests for

SARS-CoV-2: a living systematic review and meta-analysis. Clin Microbiol 574 Infect 29:291-301. 575 Bigio J, MacLean EL, Das R, Sulis G, Kohli M, Berhane S, Dinnes J, Deeks JJ, 576 14. Brümmer LE, Denkinger CM, Pai M. 2023. Accuracy of package inserts of 577 578 SARS-CoV-2 rapid antigen tests: a secondary analysis of manufacturer versus systematic review data. Lancet Microbe 4:e875-e882. 579 15. Wang X, Li Y, O'Brien KL, Madhi SA, Widdowson MA, Byass P, Omer SB, 580 Abbas Q, Ali A, Amu A, Azziz-Baumgartner E, Bassat Q, Abdullah Brooks W, 581 582 Chaves SS, Chung A, Cohen C, Echavarria M, Fasce RA, Gentile A, Gordon A, Groome M, Heikkinen T, Hirve S, Jara JH, Katz MA, Khuri-Bulos N, Krishnan A, 583 de Leon O, Lucero MG, McCracken JP, Mira-Iglesias A, Moïsi JC, Munywoki PK, 584 Ourohiré M, Polack FP, Rahi M, Rasmussen ZA, Rath BA, Saha SK, Simões EA, 585 586 Sotomayor V, Thamthitiwat S, Treurnicht FK, Wamukoya M, Yoshida LM, Zar HJ, Campbell H, Nair H. 2020. Global burden of respiratory infections 587 associated with seasonal influenza in children under 5 years in 2018: a 588 589 systematic review and modelling study. Lancet Glob Health 8:e497–e510. Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J, 590 16. Simonsen L, Viboud C. 2019. Global mortality associated with seasonal 591 592 influenza epidemics: new burden estimates and predictors from the GLaMOR 593 Project. J Glob Health 9:020421. GBD 2017 Influenza Collaborators. 2019. Mortality, morbidity, and 594 17. hospitalisations due to influenza lower respiratory tract infections, 2017: an 595 596 analysis for the Global Burden of Disease Study 2017. Lancet Respir Med 597 7:69-89.

perpetuity.

It is made available under a CC-BY 4.0 International license .

598 18. Maleki F, Welch V, Lopez SMC, Cane A, Langer J, Enstone A, Markus K, Wright O, Hewitt N, Whittle I. 2023. Understanding the global burden of 599 influenza in adults aged 18-64 years: a systematic literature review from 2012 600 to 2022. Adv Ther 40:4166-4188. 601 602 19. Gibson J, Schechter-Perkins EM, Mitchell P, Mace S, Tian Y, Williams K, Luo R, 603 Yen-Lieberman B. 2017. Multi-center evaluation of the Cobas® Liat® Influenza A/B & RSV assay for rapid point of care diagnosis. J Clin Virol 95:5— 604 9. 605 606 20. Young S, Phillips J, Griego-Fullbright C, Wagner A, Jim P, Chaudhuri S, Tang 607 S, Sickler J. 2020. Molecular point-of-care testing for influenza A/B and respiratory syncytial virus: comparison of workflow parameters for the ID 608 Now and Cobas Liat systems. J Clin Pathol 73:328–334. 609 610 21. Azar MM, Landry ML. 2018. Detection of influenza A and B viruses and 611 respiratory syncytial virus by use of Clinical Laboratory Improvement 612 Amendments of 1988 (CLIA)-waived point-of-care assays: a paradigm shift to 613 molecular tests. J Clin Microbiol 56:e00367-18. 614 22. Melchers WJG, Kuijpers J, Sickler JJ, Rahamat-Langendoen J. 2017. Lab-in-atube: real-time molecular point-of-care diagnostics for influenza A and B using 615 616 the Cobas® Liat® system. J Med Virol 89:1382–1386. 617 23. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, 618 McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT. 2019. Clinical practice 619 620 guidelines by the Infectious Diseases Society of America: 2018 update on

621 diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 68:895–902. 622 623 Berry L, Lansbury L, Gale L, Carroll AM, Lim WS. 2020. Point of care testing of 24. Influenza A/B and RSV in an adult respiratory assessment unit is associated 624 625 with improvement in isolation practices and reduction in hospital length of stay. J Med Microbiol 69:697–704. 626 25. Rahamat-Langendoen J, Groenewoud H, Kuijpers J, Melchers WJG, van der 627 Wilt GJ. 2019. Impact of molecular point-of-care testing on clinical 628 629 management and in-hospital costs of patients suspected of influenza or RSV infection: a modeling study. J Med Virol 91:1408–1414. 630 26. Mikamo H, Koizumi Y, Yamagishi Y, Asai N, Miyazono Y, Shinbo T, Horie M, 631 Togashi K, Robbins EM, Hirotsu N. 2022. Comparing the Cobas Influenza A/B 632 633 Nucleic acid test for use on the Cobas Liat System (Liat) with rapid antigen tests for clinical management of Japanese patients at the point of care. PLoS 634 One 17:e0276099. 635 636 27. Roche Molecular Systems Inc. 2021. Cobas® Liat® System User Guide. 637 28. Roche Molecular Systems Inc. 2021. Instructions for use. Cobas® SARS-CoV-2. Qualitative assay for use on the Cobas® 6800/8800 Systems. P/N: 638 09179917001-07EN. 639 Roche Molecular Systems Inc. 2021. Instructions for use. Cobas® SARS-CoV-640 29. 2 & Influenza A/B. Qualitative assay for use on the Cobas® 6800/8800 641 Systems. P/N: 09233474190. 642

- 30. Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC. 2020. 643
- Comparison of the analytical sensitivity of seven commonly used commercial 644
- SARS-CoV-2 automated molecular assays. J Clin Virol 130:104578. 645
- 31. Copan Diagnostics Inc. 2020. Instructions for use. FLOQSwabs. HPC217 646
- 647 Rev.00 Date 2020.10. https://www.copanusa.com/wp-
- content/uploads/2021/03/HPC217-PI-FLOOSWAB-NO-CE-REV.00-2020.10.pdf. 648
- Accessed Aug 5, 2024. 649
- Centers for Disease Control and Prevention. 2023. 2021-2022 flu season 650 32.
- 651 summary. https://www.cdc.gov/flu/season/fag-flu-season-2021-
- 2022.htm#print. Accessed Aug 05, 2024. 652
- 33. Dzung A, Cheng PF, Stoffel C, Tastanova A, Turko P, Levesgue MP, Bosshard 653
- 654 PP. 2021. Prolonged unfrozen storage and repeated freeze-thawing of SARS-
- 655 CoV-2 patient samples have minor effects on SARS-CoV-2 detectability by RT-
- PCR. J Mol Diagn 23:691-697. 656
- Roche Molecular Systems Inc. 2020. Instructions for use. Cobas® SARS-CoV-657 34.
- 658 2 & Influenza A/B. Nucleic acid test for use on the Cobas® Liat® System.
- P/N: 09211101190. 659
- Hologic. 2020. Instructions for use. Aptima® SARS-CoV-2 Assay (Panther® 660 35.
- 661 System).
- 662 36. Wilson E. 1927. Probable inference, the law of succession, and statistical
- inference. J Am Stat Assoc 22:209-212. 663
- 664 37. Akashi Y, Horie M, Kiyotaki J, Takeuchi Y, Togashi K, Adachi Y, Ueda A,
- Notake S, Nakamura K, Terada N, Kurihara Y, Kiyasu Y, Suzuki H. 2022. 665

Clinical performance of the cobas Liat SARS-CoV-2 & Influenza A/B Assay in 666 667 nasal samples. Mol Diagn Ther 26:323-331. Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, Westblade LF, 668 38. Jin R, Love N, Ding K, Garg S, Huang A, Sickler J, Tran NK. 2021. Clinical 669 670 performance of the point-of-care Cobas Liat for detection of SARS-CoV-2 in 20 minutes: a multicenter study. J Clin Microbiol 59:e02811-20. 671 39. Park K, Sung H, Kim MN. 2023. Evaluation of the cobas Liat detection test for 672 SARS-CoV-2 and influenza viruses following the emergence of the SARS-CoV-673 674 2 Omicron variant. Diagn Microbiol Infect Dis 105:115891. 675 40. Er TK, Chou YC, Chen SY, Huang JW. 2021. Rapid cobas Liat SARS-CoV-2 assay in comparison with the laboratory-developed real-time RT-PCR test. Clin 676 Lab 67. 677 678 41. Matic N, Lawson T, Ritchie G, Lowe CF, Romney MG. 2024. Testing the limits of multiplex respiratory virus assays for SARS-CoV-2 at high cycle threshold 679 680 values: Comparative performance of Cobas 6800/8800 SARS-CoV-2 & 681 Influenza A/B, Xpert Xpress SARS-CoV-2/Flu/RSV, and Cobas Liat SARS-CoV-2 & Influenza A/B. J Assoc Med Microbiol Infect Dis Can 8:328-335. 682 42. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. 2021. 683 684 Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2 685 molecular detection: a systematic review and meta-analysis. J Clin Microbiol 59:e02881-20. 686 Therchilsen JH, von Buchwald C, Koch A, Dam Nielsen S, Rasmussen DB, 687 43. 688 Thudium RF, Kirkby NS, Raaschou-Pedersen DET, Bundgaard JS, Iversen K, 689 Bundgaard H, Todsen T. 2020. Self-collected versus healthcare worker690 collected swabs in the diagnosis of severe acute respiratory syndrome 691 coronavirus 2. Diagnostics 10:678. 692 Craney AR, Velu PD, Satlin MJ, Fauntleroy KA, Callan K, Robertson A, La Spina 44. M, Lei B, Chen A, Alston T, Rozman A, Loda M, Rennert H, Cushing M, 693 694 Westblade LF. 2020. Comparison of two high-throughput reverse transcription-PCR systems for the detection of severe acute respiratory 695 696 syndrome coronavirus 2. J Clin Microbiol 58:e00890-20. 45. Buchta C, Zeichhardt H, Badrick T, Coucke W, Wojtalewicz N, Griesmacher A, 697 698 Aberle SW, Schellenberg I, Jacobs E, Nordin G, Schweiger C, Schwenoha K, Luppa PB, Gassner UM, Wagner T, Kammel M. 2023. Classification of "near-699 700 patient" and "point-of-care" SARS-CoV-2 nucleic acid amplification test 701 systems and a first approach to evaluate their analytical independence of 702 operator activities. J Clin Virol 165:105521. 703 May L, Robbins EM, Canchola JA, Chugh K, Tran NK. 2023. A study to assess 46. the impact of the Cobas point-of-care RT-PCR assay (SARS-CoV-2 and 704 705 Influenza A/B) on patient clinical management in the emergency department 706 of the University of California at Davis Medical Center. J Clin Virol 707 168:105597. 708 47. Jian MJ, Chung HY, Chang CK, Lin JC, Yeh KM, Chen CW, Li SY, Hsieh SS, Liu 709 MT, Yang JR, Tang SH, Perng CL, Chang FY, Shang HS. 2021. Clinical comparison of three sample-to-answer systems for detecting SARS-CoV-2 in 710 711 B.1.1.7 lineage emergence. Infect Drug Resist 14:3255–3261.

712 48. Perlitz B, Slagman A, Hitzek J, Riedlinger D, Möckel M. 2021. Point-of-care 713 testing for influenza in a university emergency department: a prospective study. Influenza Other Respir Viruses 15:608-617. 714 Yan X, Li K, Lei Z, Luo J, Wang Q, Wei S. 2023. Prevalence and associated 715 49. outcomes of coinfection between SARS-CoV-2 and influenza: a systematic 716 review and meta-analysis. Int J Infect Dis 136:29-36. 717 718